Terns Pharmaceuticals (TERN) Accumulated Depreciation & Amortization (2020 - 2025)
Terns Pharmaceuticals filings provide 6 years of Accumulated Depreciation & Amortization readings, the most recent being $682000.0 for Q4 2025.
- Quarterly Accumulated Depreciation & Amortization fell 63.95% to $682000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $682000.0 through Dec 2025, down 63.95% year-over-year, with the annual reading at $682000.0 for FY2025, 63.95% down from the prior year.
- Accumulated Depreciation & Amortization hit $682000.0 in Q4 2025 for Terns Pharmaceuticals, down from $1.9 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $1.9 million in Q4 2024 and bottomed at $682000.0 in Q4 2025.
- Average Accumulated Depreciation & Amortization over 5 years is $1.4 million, with a median of $1.4 million recorded in 2022.
- The largest annual shift saw Accumulated Depreciation & Amortization soared 71.99% in 2021 before it tumbled 63.95% in 2025.
- Terns Pharmaceuticals' Accumulated Depreciation & Amortization stood at $1.2 million in 2021, then rose by 18.31% to $1.4 million in 2022, then rose by 14.76% to $1.6 million in 2023, then grew by 17.59% to $1.9 million in 2024, then tumbled by 63.95% to $682000.0 in 2025.
- Per Business Quant, the three most recent readings for TERN's Accumulated Depreciation & Amortization are $682000.0 (Q4 2025), $1.9 million (Q4 2024), and $1.6 million (Q4 2023).